The ability of exenatide to dose-dependently suppress inappropriately-elevated glucagon secretion was demonstrated in patients with T2DM in a number of clinical pharmacology studies [61,62,63,69,80]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.